Weekly Outlook, 4-23
Seeking Alpha Analyst Since 2010
I didn't watch the market much this week, as I was out of town. It seemed to have a strong week. Right now, the market isn't trending. This is a great time to be looking for investments, because some overbought companies will use this sideways period as a time for pullback, and other companies will continue to soar through the market's consolidation. I used my time off this week to write a scathing report of Navigant Consulting <a href="seekingalpha.com/instablog/596900-charli...;>here</a>. Management is paying top dollar for mediocre performance that shows no sign of abating. With this in mind, I sold my stake in both the model portfolio and my own real portfolio for about a 9% gain, which was decent. That left me with a large cash position which I used to enter new positions. I bought 500 shares of Guess? [GES], which has been outperforming the apparel industry for years, and has a strong brand. I also bought 400 shares of AstraZeneca [AZN], which has the same pros as Guess. I placed an order to buy 350 shares of Eli Lilly. This purchase spreads my bets around the drug manufacturing industry, which has underperformed. The poor performance of the industry as a whole has dragged down some great names, including these two. Both pay over 5% in dividends and are cheap. My purchase of Eli Lilly is smaller because it earns lower returns on capital than AstraZeneca. Even with these purchases, I should have roughly $20,700 in cash. With that last bit of cash I plan to enter into a trade of Bank of America [BAC]. I will place a tight stop to manage risk with this financially troubled behemoth. Cheers.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.